Mindfulness-based cognitive therapy for patients with medically unexplained symptoms: A cost-effectiveness study

Journal of Psychosomatic Research

Volumn 74, Issue 3, 2013, Pages 197-205

  van Ravesteijn, Hiske ^a   Grutters, Janneke ^a   olde Hartman, Tim ^a   Lucassen, Peter ^a   Bor, Hans ^a   van Weel, Chris ^a   van der Wilt, Gert Jan ^a   Speckens, Anne ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cost effectiveness; Medically unexplained symptoms; Mindfulness; Somatoform disorders

Indexed keywords

ADULT; ANXIETY DISORDER; ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; EMPLOYMENT STATUS; FEMALE; FOLLOW UP; HEALTH CARE COST; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICALLY UNEXPLAINED SYMPTOM; MENTAL DISEASE; MENTAL HEALTH CARE; MINDFULNESS BASED COGNITIVE THERAPY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; UNEMPLOYMENT;

ADULT; COGNITIVE THERAPY; COST-BENEFIT ANALYSIS; EXERCISE THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDITATION; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; SOMATOFORM DISORDERS; TREATMENT OUTCOME;

EID: 84874243995     PISSN: 00223999     EISSN: 18791360     Source Type: Journal    
DOI: 10.1016/j.jpsychores.2013.01.001     Document Type: Article

References (45)

1. de Waal MW, Arnold IA, Eekhof JA, van Hemert AM Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. Br J Psychiatry 2004, 184:470-476.
2. Barsky AJ, Borus JF Somatization and medicalization in the era of managed care. JAMA 1995, 274:1931-1934.
3. Spitzer RL, Williams JB, Kroenke K, Linzer M, deGruy FV, Hahn SR, et al. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 Study. JAMA 1994, 272:1749-1756.
4. Verhaak PF, Meijer SA, Visser AP, Wolters G Persistent presentation of medically unexplained symptoms in general practice. Fam Pract 2006, 23:414-420.
5. Ring A, Dowrick CF, Humphris GM, Davies J, Salmon P The somatising effect of clinical consultation: what patients and doctors say and do not say when patients present medically unexplained physical symptoms. Soc Sci Med 2005, 61:1505-1515.
6. Konnopka A, Schaefert R, Heinrich S, Kaufmann C, Luppa M, Herzog W, et al. Economics of medically unexplained symptoms: a systematic review of the literature. Psychother Psychosom 2012, 81:265-275.
7. Barsky AJ, Orav EJ, Bates DW Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Arch Gen Psychiatry 2005, 62:903-910.
8. Barsky AJ, Ettner SL, Horsky J, Bates DW Resource utilization of patients with hypochondriacal health anxiety and somatization. Med Care 2001, 39:705-715.
9. Reid S, Wessely S, Crayford T, Hotopf M Frequent attenders with medically unexplained symptoms: service use and costs in secondary care. Br J Psychiatry 2002, 180:248-253.
10. Page LA, Wessely S Medically unexplained symptoms: exacerbating factors in the doctor-patient encounter. J R Soc Med 2003, 96:223-227.
11. Bermingham SL, Cohen A, Hague J, Parsonage M The cost of somatisation among the working-age population in England for the year 2008-2009. Ment Health Fam Med 2010, 7:71-84.
12. Edwards TM, Stern A, Clarke DD, Ivbijaro G, Kasney LM The treatment of patients with medically unexplained symptoms in primary care: a review of the literature. Ment Health Fam Med 2010, 7:209-221.
13. van Ravesteijn HJ, Lucassen PLBJ, Bor H, van Weel C, Speckens AE. Mindfulness-based cognitive therapy (MBCT) for patients with medically unexplained symptoms: a randomized controlled trial. submitted for publication.
14. Deary V, Chalder T, Sharpe M The cognitive behavioural model of medically unexplained symptoms: a theoretical and empirical review. Clin Psychol Rev 2007, 27:781-797.
15. Fjorback LO Mindfulness and bodily distress 2012, Aarhus University, Aarhus.
16. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59:22-33. [quiz 4-57].
17. First Michael B, Spitzer Robert L, Miriam Gibbon, Williams JanetBW Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version 1996, American Psychiatric Press, Inc., Washington, D.C.
18. Ware JE SF-36 health survey update. Spine (Phila Pa 1976) 2000, 25:3130-3139.
19. Teasdale JD, Segal ZV, Williams JM, Ridgeway VA, Soulsby JM, Lau MA Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol 2000, 68:615-623.
20. Kabat-Zinn J Full catastrophe living, how to cope with stress, pain and illness using mindfulness meditation 1990, Bantam Doubleday Dell Publishing.
21. Huijbers MJ, Spijker J, Donders AR, van Schaik DJ, van Oppen P, Ruhe HG, et al. Preventing relapse in recurrent depression using mindfulness-based cognitive therapy, antidepressant medication or the combination: trial design and protocol of the MOMENT study. BMC Psychiatry 2012, 12:125.
22. Freedland KE, Mohr DC, Davidson KW, Schwartz JE Usual and unusual care: existing practice control groups in randomized controlled trials of behavioral interventions. Psychosom Med 2011, 73:323-335.
23. Hakkaart- van Roijen L, Tan SS, Bouwmans CAM Institute for Medical Technology Assessment, Erasmus University Rotterdam. Handleiding voor kostenonderzoek. Methoden en standaard kostprijzen voor economisch evaluaties in de gezondheidszorg 2010, Erasmus University Rotterdam, Handleiding, [[in Dutch] actualized version].
24. Cv Zorgverzekeringen Insurances BoDHC [cited 2012]. http://www.fk.cvz.nl/.
25. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L The friction cost method for measuring indirect costs of disease. J Health Econ 1995, 14:171-189.
26. Brazier J, Usherwood T, Harper R, Thomas K Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998, 51:1115-1128.
27. Brazier J, Roberts J, Deverill M The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002, 21:271-292.
28. Drummond MF, MJ Sculpher, Torrance GW, O'Brien BJ, Stoddart GL Methods for the economic evaluation of health care programmes 2005, Oxford University Press, Oxford.
29. Briggs AH, Wonderling DE, Mooney CZ Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997, 6:327-340.
30. Efron B, Tibshirani R An introduction to the bootstrap 1993, Chapmann & Hall.
31. van Hout BA, Al MJ, Gordon GS, Rutten FF Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994, 3:309-319.
32. Kuyken W, Byford S, Taylor RS, Watkins E, Holden E, White K, et al. Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. J Consult Clin Psychol 2008, 76:966-978.
33. Care CfPHaH Sensible and sustainable care (in Dutch) 2006, Council for Public Health and Health Care, Zoetermeer.
34. Walters SJ, Brazier JE Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005, 14:1523-1532.
35. Gyrd-Hansen D Willingness to pay for a QALY. Health Econ 2003, 12:1049-1060.
36. Laupacis A, Feeny D, Detsky AS, Tugwell PX How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992, 146:473-481.
37. King JT, Tsevat J, Lave JR, Roberts MS Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making 2005, 25:667-677.
38. Devlin N, Parkin D Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004, 13:437-452.
39. Luo Z, Goddeeris J, Gardiner JC, Smith RC Costs of an intervention for primary care patients with medically unexplained symptoms: a randomized controlled trial. Psychiatr Serv 2007, 58:1079-1086.
40. Manca A, Palmer S Handling missing data in patient-level cost-effectiveness analysis alongside randomised clinical trials. Appl Health Econ Health Policy 2005, 4:65-75.
41. van Ravesteijn HJ, Suijkerbuijk YB, Langbroek JA, Muskens E, Lucassen PLBJ, van Weel C, et al. Mindfulness-based cognitive therapy (MBCT) for patients with medically unexplained symptoms: a longitudinal qualitative study. submitted for publication.
42. van Asselt AD, Dirksen CD, Arntz A, Severens JL Difficulties in calculating productivity costs: work disability associated with borderline personality disorder. Value Health 2008, 11:637-644.
43. Brouwer WB, Koopmanschap MA The friction-cost method: replacement for nothing and leisure for free?. Pharmacoeconomics 2005, 23:105-111.
44. Zhang W, Bansback N, Anis AH Measuring and valuing productivity loss due to poor health: a critical review. Soc Sci Med 2011, 72:185-192.
45. Sculpher MJ, Claxton K, Drummond M, McCabe C Whither trial-based economic evaluation for health care decision making?. Health Econ 2006, 15:677-687.